The 177Lu SPECT/CT Accreditation pilot study is now undergoing!
We extend our gratitude to all the centres that expressed interest.
Join us for the EARL session to see the results from this groundbreaking study at the Annual Congress this October.
What our experts say on the importance of this new accreditation: https://youtu.be/OkV-XKNbxZI
The field of 177Lu radiopharmaceutical therapy is rapidly expanding, which is reflected in the increased use of existing radioligands such as [177Lu]Lu-DOTATATE or [177Lu]Lu-PSMA, with new ones such as [177Lu]Lu-FAPI already in development. Post-therapy quantitative SPECT-CT is important for treatment verification, dosimetry, and trials requiring information on the pharmacokinetics. However, SPECT-CT imaging protocols for 177Lu are not standardised, which hampers scientific progress in this rapidly developing field. EANM/EARL has therefore formed a task group to define a standardisation and harmonisation programme for quantitative 177Lu SPECT-CT. The group has proposed a specific protocol, and is in the process of validating it.
The following file contains the proposed protocol. More details will be shared at the EANM’22 congress. EARL_QSPECT_15Mar22